A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.

CPT Pharmacometrics Syst Pharmacol · 2015 · PMC4759707 · PMID 26904385

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

Study effect was highly significant in univariate analysis ( P < 0.0001), but no longer in the final model after adjustment of the covariate effects ( P ≥ 0.02).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.